Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Pfizer Covid-19 Pill Receives Emergency Use Authorization From FDA

Published 12/22/2021, 12:14 PM
Updated 12/22/2021, 12:22 PM
© Reuters

By Yasin Ebrahim

Investing.com - Pfizer on Wednesday received emergency use authorization for its Covid-19 pill Paxlovid to treat mild-to-moderate coronavirus disease in adults and patients of at least 12 years of age.

Shares of Pfizer (NYSE:PFE) were up more than 2%.

“Today’s authorization introduces the first treatment for COVID-19 that is in the form of a pill that is taken orally — a major step forward in the fight against this global pandemic,” said Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research.

“This authorization provides a new tool to combat COVID-19 at a crucial time in the pandemic as new variants emerge and promises to make antiviral treatment more accessible to patients who are at high risk for progression to severe COVID-19.” 

Paxlovid was shown to significantly reduced the risk of COVID-19 related hospitalization or death by 88% compared to placebo among patients treated within five days of symptom onset and who didn't receive COVID-19 therapeutic monoclonal antibody treatment. 

 

Latest comments

Wonder how many people will die as a result of the suicide pill. I trust Ivermectin combined with remdesivir and some other stuff more than the creators of Myocarditis
the biggest criminal organization gets more push 👍
finally
yea- this will work alright
You can refuse any medication vaccines or masks just don't go into the hospital when you are sick. Die at home so I can get my back operated on. 👍
 Yes and others can get their cancer treatments or diagnosis. Several people I know have had delays getting these types of tests and treatments due to staffing issues.
It's a universal problem.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.